Background levels of Persistent Organic Pollutants in humans from Taiwan: Perfluorooctane sulfonate and perfluorooctanoic acid

Hsu, Jen Yi; Hsu, Jing‐Fang; Ho, Hsin Hui; Chiang, Chung-Jen; Liao, Pao Chi

doi:10.1016/j.chemosphere.2013.06.047

Cited by 25 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, more studies are needed to investigate the relation between PFC value and the age of affected people. In Taiwan, the serum concentration of PFOA was 3.22 ng/mL and that of PFOS was 8.52 ng/mL in healthy people, which are similar to levels in other countries (PFOA: 1.5 ± 10 ng/mL, PFOS: 5.0 ± 35 ng/mL) [ 26 ].…”

Section: Discussionsupporting

confidence: 66%

See 1 more Smart Citation

Dialysis Membranes Influence Perfluorochemical Concentrations and Liver Function in Patients on Hemodialysis

Liu

Chan

Lai

et al. 2018

IJERPH

View full text Add to dashboard Cite

Introduction: Perfluoro-octanesulfonate (PFOS) and perfluoro-octanoic acid (PFOA) are two toxic perfluorochemicals (PFCs) commonly used as surfactants. PFCs are difficult to be eliminated from the body. We investigated the influence of different dialysis membranes on the concentrations of PFCs in patients under hemodialysis. Method: We enrolled 98 patients. Of these, 58 patients used hydrophobic polysulfone (PS) dialysis membranes, and the other 40 had hydrophilic membranes made by poly-methyl methacrylate (PMMA) or cellulose triacetate (CTA). Liquid chromatography tandem mass spectrometry coupled was used with isotope dilution to quantify PFOA and PFOS. Results: The predialysis concentrations of PFOA and PFOS in patients with hydrophobic PS dialysis membranes were 0.50 and 15.77 ng/mL, respectively, lower than the concentrations of 0.81 and 22.70 ng/mL, respectively, in those who used hydrophilic membranes (such as CTA or PMMA). Older patients have higher PFOS and poorer body function, with lower Karnofsky Performance Status Scale (KPSS) scores. The demographic data of the two groups were similar. However, patients with hydrophobic PS dialysis membranes had lower predialysis aspartate transaminase (AST) (p = 0.036), lower glucose levels (p = 0.017), and better body function (nonsignificantly higher KPSS scores, p = 0.091) compared with patients who used other membranes. These differences may be associated with the effects of different membranes, because PFOA positively correlated with AST, while PFOS negatively correlated with body function. Conclusions: This is the first study comparing PFC levels in uremic patients with different dialysis membrane. PS membrane may provide better clearance of PFCs and may, therefore, be beneficial for patients.

show abstract

Section: Discussionsupporting

confidence: 66%

“…In modern society, younger generations may encounter many more products with PFOA than in previous years. Studies showed that PFC levels are higher in children than in adults in Taiwan [ 26 ]. In 2014, PFC levels in serum samples from Taiwanese children was also higher than that observed between 2006 and 2008 [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Dialysis Membranes Influence Perfluorochemical Concentrations and Liver Function in Patients on Hemodialysis

Liu

Chan

Lai

et al. 2018

IJERPH

View full text Add to dashboard Cite

show abstract

“…In previous studies in Taiwan, the serum concentration of PFOA was 3.22 ng/ml and that of PFOS was 8.52 ng/ml in healthy people, which are similar to levels in other countries. (PFOA: 1.5–10 ng/mL, PFOS: 5.0–35 ng/mL) [ 23 ]. In Korea, the concentration of PFOA was 2.85 ng/ml and PFOS was 10.23 ng/ml in the general population[ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Associations between perfluorinated chemicals and serum biochemical markers and performance status in uremic patients under hemodialysis

et al. 2018

View full text Add to dashboard Cite

Perfluorooctanesulfonate (PFOS) and perfluorooctanoic acid (PFOA) are commonly used perfluorinated chemicals (PFCs). PFCs are mainly excreted by urine. Uremic patients tend to accumulate toxins in their body and have poor functional status. We investigated the associations between PFCs and the clinical profile of uremic patients under hemodialysis (HD). Liquid chromatography tandem mass spectrometry coupled with isotope dilution was used to quantify PFOA and PFOS. We enrolled 126 patients under regular HD. Compared with previous research, the concentration of PFOA was lower, but that of PFOS was higher in uremic patients than in the general population. The levels of PFOA and PFOS in uremic patients before dialysis were 0.52 (ng/ml) and 21.84 (ng/ml) respectively. The PFOA level remained unchanged but that of PFOS decreased to1.85 ng/mL after dialysis. PFOS can be removed by HD. Patients using hypertensive medication had a lower PFOS then those who did not. The PFOS level was negatively correlated with the duration of the HD session and patient performance status, but positively correlated with levels of cholesterol, chloride (an indicator of acidemia), ferritin, and total protein. (p<0.05). The association with serum protein may explain the long half-life of PFCs in humans. This is the first study which investigated PFCs in uremic patients and showed PFCs are associated with adverse effects in this population.

show abstract

“…It is not clear whether increased membrane permeability influences the interaction of PFOS or PFOA with E2 activity in the present study. However, we find it interesting that relatively low concentrations (10 −9 to 10 −7 M) of PFOS and PFOA modulated the E2 functions in the present study, which is relevant to the mean serum concentrations of both compounds in the general population (9.3 × 10 −9 to 6.5 × 10 −8 M for PFOS and 3.5 × 10 −9 to 2.4 × 10 −8 M for PFOA) (Hsu et al ., ). Although the relationships between PFC exposure and disease are still not clear, estrogen‐related diseases should receive more attention because in vitro studies have shown that E2 functions are altered in the presence of PFOS and PFOA in both humans and animals.…”

Section: Discussionmentioning

confidence: 97%

Perfluorinated chemicals, PFOS and PFOA, enhance the estrogenic effects of 17β‐estradiol in T47D human breast cancer cells

Sonthithai

Suriyo

Thiantanawat

et al. 2015

J of Applied Toxicology

View full text Add to dashboard Cite

Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) are the two most popular surfactants among perfluorinated compounds (PFCs), with a wide range of uses. Growing evidence suggests that PFCs have the potential to interfere with estrogen homeostasis, posing a risk of endocrine-disrupting effects. This in vitro study aimed to investigate the estrogenic effect of these compounds on T47D hormone-dependent breast cancer cells. PFOS and PFOA (10(-12) to 10(-4) M) were not able to induce estrogen response element (ERE) activation in the ERE luciferase reporter assay. The ERE activation was induced when the cells were co-incubated with PFOS (10(-10) to 10(-7) M) or PFOA (10(-9) to 10(-7) M) and 1 nM of 17β-estradiol (E2). PFOS and PFOA did not modulate the expression of estrogen-responsive genes, including progesterone (PR) and trefoil factor (pS2), but these compounds enhanced the effect of E2-induced pS2 gene expression. Neither PFOS nor PFOA affected T47D cell viability at any of the tested concentrations. In contrast, co-exposure with PFOS or PFOA and E2 resulted in an increase of E2-induced cell viability, but no effect was found with 10 ng ml(-1) EGF co-exposure. Both compounds also intensified E2-dependent growth in the proliferation assay. ERK1/2 phosphorylation was increased by co-exposure with PFOS or PFOA and E2, but not with EGF. Collectively, this study shows that PFOS and PFOA did not possess estrogenic activity, but they enhanced the effects of E2 on estrogen-responsive gene expression, ERK1/2 activation and the growth of the hormone-deprived T47D cells. Copyright © 2015 John Wiley & Sons, Ltd.

show abstract

Background levels of Persistent Organic Pollutants in humans from Taiwan: Perfluorooctane sulfonate and perfluorooctanoic acid

Cited by 25 publications

References 39 publications

Dialysis Membranes Influence Perfluorochemical Concentrations and Liver Function in Patients on Hemodialysis

Dialysis Membranes Influence Perfluorochemical Concentrations and Liver Function in Patients on Hemodialysis

Associations between perfluorinated chemicals and serum biochemical markers and performance status in uremic patients under hemodialysis

Perfluorinated chemicals, PFOS and PFOA, enhance the estrogenic effects of 17β‐estradiol in T47D human breast cancer cells

Contact Info

Product

Resources

About